RenovoRx (NASDAQ:RNXT) Issues Earnings Results

RenovoRx (NASDAQ:RNXT) posted its earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08), FiscalAI reports. RenovoRx had a negative net margin of 1,196.66% and a negative return on equity of 122.19%. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.42 million. During the same quarter last year, the company earned ($0.40) earnings per share.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx achieved initial commercial traction with $1.1M in 2025 revenue, reported Q4 revenue of $238k, has 12 active U.S. centers (33-center near‑term pipeline) and is targeting ~36 active sites by year‑end 2026 with company guidance that 2026 revenue should be roughly $3M–$4M.
• The company strengthened its balance sheet with an oversubscribed private placement closing on March 23, 2026 that raised ~$10M gross, supplementing ~$7M cash at year‑end 2025 to fund commercial scale‑up and TIGeR‑PaC completion.
• The Phase III TIGeR‑PaC trial is nearing its enrollment target (104 of 114 randomized as of March 24, 2026) with 72 of 86 events observed and final data expected in 2027, representing a material clinical catalyst if positive.
• Near‑term revenue remains lumpy and scale‑constrained (quarterly results swing based on a small number of active centers and timing of first patient treatments), while R&D and SG&A run rates and the need to convert trial sites to commercial use pose execution and dilution risks if commercial adoption is slower than planned.

RenovoRx Trading Down 5.3%

Shares of NASDAQ:RNXT traded down $0.06 on Tuesday, reaching $1.01. 456,183 shares of the company traded hands, compared to its average volume of 343,224. The stock has a market capitalization of $37.13 million, a P/E ratio of -2.82 and a beta of 1.34. The business’s 50-day simple moving average is $0.95 and its 200 day simple moving average is $1.01. RenovoRx has a 52 week low of $0.70 and a 52 week high of $1.45.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd boosted its position in RenovoRx by 58.6% in the fourth quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after purchasing an additional 18,525 shares during the last quarter. Bleichroeder LP lifted its stake in shares of RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after purchasing an additional 61,379 shares during the period. Wealthspire Advisors LLC purchased a new position in shares of RenovoRx in the fourth quarter worth approximately $212,000. Citadel Advisors LLC bought a new stake in RenovoRx during the third quarter valued at approximately $154,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new stake in RenovoRx during the second quarter valued at approximately $98,000. Institutional investors own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. Wall Street Zen upgraded shares of RenovoRx from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Ascendiant Capital Markets lifted their price objective on RenovoRx from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.